{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T20:25:30Z","timestamp":1781987130155,"version":"3.54.5"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.01.012","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:54:06Z","timestamp":1740171246000},"page":"412-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-0800","authenticated-orcid":false,"given":"Khi Yung","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-0651","authenticated-orcid":false,"given":"Ee Jean","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Chew","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae Jack","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie Huei Li","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Sun Sien","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Shyi Peng","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2025.01.012_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/JU.0000000000000350","article-title":"A Nationwide, Population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0004","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang Sam","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0005","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2014.12.007","article-title":"Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy","volume":"67","author":"Novara","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0006","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.juro.2017.08.111","article-title":"Health related quality of life following radical cystectomy: comparative analysis from the medicare health outcomes survey","volume":"199","author":"Winters","year":"2018","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.012_bib0007","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/JU.0000000000001360","article-title":"Electronic rapid fitness assessment identifies factors associated with adverse early postoperative outcomes following radical cystectomy","volume":"205","author":"Chesnut Gregory","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0008","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.euf.2017.12.011","article-title":"A simplified frailty index to predict outcomes after radical cystectomy","volume":"5","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"35","key":"10.1016\/j.urolonc.2025.01.012_bib0009","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"R\u00f6del","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.012_bib0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216255","article-title":"Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: does the current quality of evidence justify definitive conclusions?","volume":"14","author":"Wettstein","year":"2019","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.urolonc.2025.01.012_bib0015","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic Bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.012_bib0017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0018","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","article-title":"Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base","volume":"88","author":"Gray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.urolonc.2025.01.012_bib0019","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement","volume":"313","author":"Stewart","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0021","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0022","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0023","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1191\/1740774505cn087oa","article-title":"Meta-analysis of individual patient data from randomized trials: a review of methods used in practice","volume":"2","author":"Simmonds","year":"2005","journal-title":"Clin Trials"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0024","doi-asserted-by":"crossref","first-page":"c221","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"issue":"0","key":"10.1016\/j.urolonc.2025.01.012_bib0025","article-title":"Subcutaneous versus transvenous implantable defibrillator therapy: a systematic review and meta-analysis of randomized trials and propensity score\u2013Matched studies","volume":"0","author":"Fong","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0027","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.01.012_bib0031","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamacardio.2017.2922","article-title":"Restricted mean survival time as a measure to interpret clinical trial results","volume":"2","author":"Kim","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"19","key":"10.1016\/j.urolonc.2025.01.012_bib0032","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"issue":"7414","key":"10.1016\/j.urolonc.2025.01.012_bib0033","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res Ed)"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0034","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid-Based Healthcare"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S1460396914000107","article-title":"Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer","volume":"13","author":"Al Gizawy","year":"2014","journal-title":"J Radiother Pract"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0036","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jval.2013.01.005","article-title":"Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research","volume":"16","author":"Bekelman","year":"2013","journal-title":"Value Health"},{"issue":"16","key":"10.1016\/j.urolonc.2025.01.012_bib0037","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.7314\/APJCP.2014.15.16.6519","article-title":"Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer","volume":"15","author":"Ikeda","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"40","key":"10.1016\/j.urolonc.2025.01.012_bib0038","doi-asserted-by":"crossref","first-page":"68996","DOI":"10.18632\/oncotarget.16576","article-title":"Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.urolonc.2025.01.012_bib0039","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with Cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.01.012_bib0042","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0043","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000471","article-title":"Comparison of outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preservation","volume":"42","author":"Zhong","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0044","doi-asserted-by":"crossref","first-page":"19.e11","DOI":"10.1016\/j.urolonc.2014.09.014","article-title":"Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study","volume":"33","author":"Gofrit","year":"2015","journal-title":"Urol Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.01.012_bib0045","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0046","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.clgc.2021.03.010","article-title":"Radical cystectomy vs. Multimodality treatment in T2N0M0 bladder cancer: a population-based, age-matched analysis","volume":"19","author":"Deuker","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0047","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fonc.2019.01315","article-title":"Evaluation of survival outcomes with trimodal therapy as primary therapy for non-organ-confined bladder cancer","volume":"9","author":"Guo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0048","first-page":"30","article-title":"Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: an analysis of the National Cancer Database","volume":"26","author":"Janopaul-Naylor","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0049","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.14109","article-title":"Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer","volume":"121","author":"Ritch","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.012_bib0051","doi-asserted-by":"crossref","first-page":"272.e271","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0052","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0053","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12957-023-03161-z","article-title":"Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis","volume":"21","author":"Su","year":"2023","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.urolonc.2025.01.012_bib0054","doi-asserted-by":"crossref","first-page":"564779","DOI":"10.3389\/fonc.2020.564779","article-title":"Trimodal therapy vs. Radical cystectomy for muscle-invasive bladder cancer: a meta-analysis","volume":"10","author":"Ding","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1464-410X.2012.11762.x","article-title":"Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy","volume":"112","author":"Smith","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.012_bib0056","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0057","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semradonc.2004.07.008","article-title":"Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates\u2013the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences","volume":"15","author":"Shipley","year":"2005","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.012_bib0058","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOU.0000000000000203","article-title":"Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?","volume":"25","author":"Mathieu","year":"2015","journal-title":"Curr Opin Urol"},{"issue":"34","key":"10.1016\/j.urolonc.2025.01.012_bib0059","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.012_bib0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.012_bib0061","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.012_bib0062","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00345-020-03436-0","article-title":"Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"39","author":"Schuettfort","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.012_bib0063","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","article-title":"Trimodality therapy in bladder cancer: who, what, and when?","volume":"42","author":"Premo","year":"2015","journal-title":"Urol Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.012_bib0064","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clgc.2018.09.023","article-title":"Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer","volume":"17","author":"Royce","year":"2019","journal-title":"Clin Genitourin Ca"},{"issue":"10","key":"10.1016\/j.urolonc.2025.01.012_bib0065","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.012_bib0066","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/UPJ.0000000000000403","article-title":"Cost of bladder cancer care: a single-center comparison of radical cystectomy and trimodal therapy","volume":"10","author":"Magee","year":"2023","journal-title":"Urol Pract"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:42:48Z","timestamp":1748443368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143925000110"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}